Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621621 · ClinicalTrials.gov registry record · Phase 4
CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)
A Phase 4 study of Tachycardia, Atrioventricular Nodal Reentry, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- Phase 4
- Development phase
- 105
- Enrollment target
- 4
- Study locations
NCT00621621: Completed Phase 4 study of Tachycardia, Atrioventricular Nodal Reentry, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT00621621 is a Phase 4 study of Tachycardia, Atrioventricular Nodal Reentry that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 105 participants. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00621621, a Phase 4 study of Tachycardia, Atrioventricular Nodal Reentry, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 105 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this post approval study of heart block is to gather additional information regarding how often patients develop heart block (atrioventricular block) after having standard ablation procedure using cryotherapy with the Freezor™ catheter.
Conditions Studied
Interventions
- DEVICE Freezor® Cardiac Cryoablation Catheter CryoConsole System
Study Locations (4)
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- Columbia University Medical Center and the New York Presbyterian Hospital - New York
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2006-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00621621
The ClinicalTrials.gov registry entry for NCT00621621 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tachycardia, Atrioventricular Nodal Reentry appearing as the primary indexed condition, and to 1 intervention - of which Freezor® Cardiac Cryoablation Catheter CryoConsole System is the first listed.
NCT00621621 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Minnesota, Nebraska, New York.
Frequently Asked Questions
What is clinical trial NCT00621621 about?
NCT00621621 is a clinical study titled "CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)". The purpose of this post approval study of heart block is to gather additional information regarding how often patients develop heart block (atrioventricular block) after having standard ablation procedure using cryotherapy with the Freezor™ catheter.
What is the current status of trial NCT00621621?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 105 participants. The study started on 2006-12. Estimated completion is 2013-12.
What conditions does trial NCT00621621 study?
This clinical trial studies the following conditions: Tachycardia, Atrioventricular Nodal Reentry.
What interventions are being tested in trial NCT00621621?
The interventions under investigation include: Freezor® Cardiac Cryoablation Catheter CryoConsole System (DEVICE).
Who is sponsoring clinical trial NCT00621621?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00621621 being conducted?
This trial has 4 study locations across Minnesota, Nebraska, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.